Motivated by a series of work demonstrating the effect of molecular charge on antibody
pharmacokinetics (PK), physiological-based pharmacokinetic (PBPK) models are emerging …

Despite the clinical success of the third-generation EGFR inhibitor osimertinib as a first-line
treatment of EGFR-mutant non-small cell lung cancer (NSCLC), resistance arises due to the …

Objective Postpartum, patients with multiple sclerosis (MS) and neuromyelitis optica
spectrum disorder (NMOSD) have increased risk for disease activity. Anti‐CD20 IgG1 …

The main objective of this manuscript was to validate the ability of the monoclonal antibody
physiologically-based pharmacokinetic (PBPK) model to predict tissue concentrations of …

To systematically assess the ChatGPT large language model on diverse tasks relevant to
pharmacokinetic data analysis. ChatGPT was evaluated with prototypical tasks related to …

Functional blockade of the transforming growth factor-beta (TGF-β) signaling pathway
improves the efficacy of cytotoxic and immunotherapies. We conducted a phase 1b study to …

Functional blockade of the transforming growth factor-beta (TGFβ) signalling pathway
improves the efficacy of cytotoxic and immunotherapies. Here, we conducted a phase 1b …

To facilitate model-informed drug development (MIDD) of adeno-associated virus (AAV)
therapy, here we have developed a physiologically based pharmacokinetic (PBPK) model …

Systems models of biological networks show promise for informing drug target
selection/qualification, identifying lead compounds and factors regulating disease …

Bispecific antibodies (BAbs) are novel constructs that are under development and show
promise as new therapeutic modalities for cancer and autoimmune disorders. The aim of this …